SG11202012398UA - Influenza virus hemagglutinin mutants - Google Patents

Influenza virus hemagglutinin mutants

Info

Publication number
SG11202012398UA
SG11202012398UA SG11202012398UA SG11202012398UA SG11202012398UA SG 11202012398U A SG11202012398U A SG 11202012398UA SG 11202012398U A SG11202012398U A SG 11202012398UA SG 11202012398U A SG11202012398U A SG 11202012398UA SG 11202012398U A SG11202012398U A SG 11202012398UA
Authority
SG
Singapore
Prior art keywords
influenza virus
virus hemagglutinin
mutants
hemagglutinin mutants
influenza
Prior art date
Application number
SG11202012398UA
Other languages
English (en)
Inventor
Pierre-Olivier Lavoie
Aurélien Lorin
Alain Doucet
MARC-ANDRé D'AOUST
Manon Couture
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of SG11202012398UA publication Critical patent/SG11202012398UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202012398UA 2018-06-27 2019-06-27 Influenza virus hemagglutinin mutants SG11202012398UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690780P 2018-06-27 2018-06-27
PCT/CA2019/050893 WO2020000101A1 (fr) 2018-06-27 2019-06-27 Mutants d'hémagglutinine du virus de la grippe

Publications (1)

Publication Number Publication Date
SG11202012398UA true SG11202012398UA (en) 2021-01-28

Family

ID=68985311

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11202012349QA SG11202012349QA (en) 2018-06-27 2019-06-27 Influenza virus hemagglutinin mutants
SG11202012398UA SG11202012398UA (en) 2018-06-27 2019-06-27 Influenza virus hemagglutinin mutants
SG11202012314YA SG11202012314YA (en) 2018-06-27 2019-06-27 Influenza virus hemagglutinin mutants

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202012349QA SG11202012349QA (en) 2018-06-27 2019-06-27 Influenza virus hemagglutinin mutants

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202012314YA SG11202012314YA (en) 2018-06-27 2019-06-27 Influenza virus hemagglutinin mutants

Country Status (14)

Country Link
US (3) US20210340184A1 (fr)
EP (3) EP3814507A4 (fr)
JP (5) JP2021528970A (fr)
KR (3) KR20210025627A (fr)
CN (3) CN112534056A (fr)
AU (3) AU2019295496A1 (fr)
BR (3) BR112020026537A2 (fr)
CA (3) CA3103840A1 (fr)
IL (3) IL279719A (fr)
MX (3) MX2020013957A (fr)
PH (3) PH12020552197A1 (fr)
SG (3) SG11202012349QA (fr)
TW (3) TW202017937A (fr)
WO (3) WO2020000099A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3814507A4 (fr) * 2018-06-27 2022-07-06 Medicago Inc. Mutants d'hémagglutinine du virus de la grippe
EP3896077A1 (fr) 2020-04-16 2021-10-20 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH Particules de type virus de la grippe
WO2021249013A1 (fr) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions de vaccin, procédés et utilisations associées

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU785148B2 (en) * 1999-12-10 2006-10-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
CA2615372A1 (fr) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
EP2610345B1 (fr) * 2007-11-27 2015-08-19 Medicago Inc. Particules pseudo-virales (VLP) de la grippe recombinantes produites dans des plantes transgéniques exprimant l'hémagglutinine
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
PT2318530T (pt) * 2008-07-18 2016-09-30 Medicago Inc Novo epítopo de imunização contra o vírus da gripe
PT2760882T (pt) * 2011-09-30 2023-08-07 Medicago Inc Aumento do rendimento de partícula semelhante a vírus em plantas
WO2013130132A1 (fr) * 2011-10-07 2013-09-06 Medimmune, Llc Variants d'hémagglutinine de la grippe
US20130315955A1 (en) * 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
CN104582714A (zh) * 2012-05-23 2015-04-29 斯坦福大学托管董事会 流感疫苗构建体
CN112592389A (zh) * 2013-03-28 2021-04-02 莫迪卡戈公司 植物中流感样病毒颗粒的产生
CN107074912B (zh) * 2014-07-10 2021-10-29 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
WO2017191258A1 (fr) * 2016-05-04 2017-11-09 Curevac Ag Vaccins contre l'arnm de la grippe
WO2018073340A1 (fr) * 2016-10-19 2018-04-26 Redbiotec Ag Vaccin contre le virus de la grippe
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
EP3814507A4 (fr) * 2018-06-27 2022-07-06 Medicago Inc. Mutants d'hémagglutinine du virus de la grippe

Also Published As

Publication number Publication date
WO2020000101A1 (fr) 2020-01-02
SG11202012349QA (en) 2021-01-28
MX2020013961A (es) 2021-03-09
EP3814509A4 (fr) 2022-07-27
CN112654707A (zh) 2021-04-13
EP3814507A1 (fr) 2021-05-05
EP3814508A4 (fr) 2022-07-27
MX2020013959A (es) 2021-03-09
EP3814509A1 (fr) 2021-05-05
CA3103840A1 (fr) 2020-01-02
EP3814507A4 (fr) 2022-07-06
KR20210025626A (ko) 2021-03-09
SG11202012314YA (en) 2021-01-28
BR112020026620A8 (pt) 2022-01-25
PH12020552252A1 (en) 2021-06-07
KR20210025627A (ko) 2021-03-09
JP2024050650A (ja) 2024-04-10
US20210221853A1 (en) 2021-07-22
JP2021528972A (ja) 2021-10-28
JP2024050651A (ja) 2024-04-10
AU2019295495A1 (en) 2020-11-26
BR112020026537A2 (pt) 2021-04-06
CA3103849A1 (fr) 2020-01-02
PH12020552219A1 (en) 2021-06-28
PH12020552197A1 (en) 2021-06-28
TW202016309A (zh) 2020-05-01
AU2019295497A1 (en) 2020-11-26
WO2020000099A1 (fr) 2020-01-02
MX2020013957A (es) 2021-03-09
US20210340184A1 (en) 2021-11-04
JP2021528970A (ja) 2021-10-28
TW202017937A (zh) 2020-05-16
CA3103842A1 (fr) 2020-01-02
US20210371472A1 (en) 2021-12-02
EP3814508A1 (fr) 2021-05-05
CN112639100A (zh) 2021-04-09
BR112020026620A2 (pt) 2021-04-06
IL279719A (en) 2021-03-01
WO2020000100A1 (fr) 2020-01-02
IL279726A (en) 2021-03-01
IL279729A (en) 2021-03-01
CN112534056A (zh) 2021-03-19
TW202016308A (zh) 2020-05-01
KR20210024625A (ko) 2021-03-05
AU2019295496A1 (en) 2020-11-26
BR112020026638A2 (pt) 2021-04-06
JP2021528971A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
EP3538146A4 (fr) Vaccin antigrippal
EP3609534A4 (fr) Vaccin à large spectre contre le virus de la grippe
IL267949A (en) Altered virus
EP3365007A4 (fr) Vaccin contre le virus de la grippe à large spectre
EP3463447A4 (fr) Régimes de vaccination contre le virus de la grippe
EP3247389A4 (fr) Régimes de vaccination contre le virus de la grippe
EP3471767A4 (fr) Hémagglutinines du virus de la grippe et utilisations de celles-ci
IL279726A (en) The hemagglutinin mutants of the influenza virus
EP3528827A4 (fr) Vaccins contre la grippe à base de protéine hémagglutinine
IL267785A (en) virus
ZA202004538B (en) Influenza virus vaccines and uses thereof
IL280332A (en) A preparation containing a flu vaccine
EP3562498A4 (fr) Vaccins contre la grippe
EP3423090C0 (fr) Nouveaux antigènes de la grippe
EP3866847A4 (fr) Vaccin antiviral
GB201820983D0 (en) Virus
HK1249864A1 (zh) 流感a/shanghai/2/2013 h7序列的改性h7血凝素糖蛋白
IL255542B (en) Influenza virus neutralizing peptidomimetic compounds
KR101921384B9 (ko) 인플루엔자 바이러스 표면 단백질 헤마글루티닌 단량체를 포함하는 오소믹소바이러스에 대한 항원 조성물
EP3585884A4 (fr) Mutants du virus de la grippe b et utilisations
AU2018903913A0 (en) Virus Vaccine
HK1246806A1 (zh) 中和流感病毒的擬肽化合物
GB201716047D0 (en) Virus
GB201615311D0 (en) Virus, Vaccine cures
GB201700259D0 (en) Virus